Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia
Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational cancer drug obinutuzumab met its primary endpoint and an additional futility analysis suggested that it could show superiority compared to the company’s currently marketed MabThera/Rituxan (rituximab) in first line chronic lymphatic leukemia (CLL).
Cancer and rheumatoid arthritis drug MabThera generated sales last year of 6.7 billion Swiss francs ($7.4 billion) but faces patent expiries in Europe from November this year and in 2018 the USA, where it is sold as Rituxan
This Phase III randomized study investigated the efficacy and safety profile of obinutuzumab (GA101) plus chlorambucil, a chemotherapy, compared with chlorambucil alone in people with previously untreated CLL. An improvement in progression-free survival (PFS) was achieved: GA101 plus chlorambucil significantly reduced the risk of disease worsening or death compared to chlorambucil alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze